Cupid Stock Surges Past ₹220 as Penny Stock Multibagger Extends Rally

Cupid Limited shares jumped 6% to ₹222 on July 10, extending a 13% two-day rally as the condom maker continued rewarding over 200,000 shareholders with multibagger returns. The stock has surged 900% in one year and 8,600% in three years. At the end of June, Cupid raised its FY27 revenue guidance to over ₹660 crore from ₹600 crore, citing strong domestic and international demand.

From penny stock to ₹87 lakh gains

Cupid traded at ₹2.43 in July 2021 and now sits at ₹213, a 8,664% climb over five years. An investor who put ₹1 lakh into the stock five years ago would have ₹87 lakh today. Year-to-date, the stock has gained 103%, while monthly gains reached 41.43%. The rally reflects disciplined execution and expanding global market access for male and female condoms, lubricants, and IVD kits.

Q1 FY27 guidance signals continued momentum

Cupid announced in late June it expects Q1 FY27 revenue to exceed ₹150 crore, marking one of its strongest quarterly performances. The company raised full-year FY27 revenue guidance by at least 10% to ₹660 crore, backed by a diversified business model and expanding international opportunity pipeline. Revenue from operations jumped 101.7% year-on-year to ₹93.49 crore in Q3 FY26, with EBITDA surging 201% to ₹34.30 crore.

Technical signals flash overbought territory

Meyka data shows CUPID.NS trading with RSI at 71, indicating overbought conditions, while the ADX reads 38.11, signaling a strong trend. The stock trades at a PE ratio of 265.3, well above sector averages, and carries a Meyka grade of B+ with a 12-month price forecast of ₹278.09. Meyka’s DCF model recommends selling, while ROE and ROA metrics suggest strong buy signals, creating mixed signals for value investors.

Why the penny stock label persists

Cupid remains classified as a penny stock despite its ₹213 price because it started below ₹5 and built its reputation on multibagger returns from that base. The company manufactures and supplies condoms globally, holding WHO and UN Population Fund prequalification for both male and female contraceptives. Its Nashik facility near Mumbai serves over 2 lakh shareholders seeking exposure to healthcare and consumer staples growth in emerging markets.

Final Thoughts

Cupid’s 900% one-year return and raised FY27 guidance support continued strength, but RSI at 71 and a PE of 265 warn of near-term pullback risk. Meyka’s B+ grade with mixed DCF and valuation signals suggests waiting for a consolidation before new entries.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.